Retatrutide 40mg Injection Pen Kit
Explore the scientific background of
Retatrutide 40mg Injection Pen Kit,
a Synedica product listing associated with
retatrutide (LY3437943), an investigational
peptide studied for its activity at
GLP-1, GIP and glucagon receptors.
Retatrutide has attracted scientific
interest in metabolic regulation,
body-weight research and hormonal
signalling. Published clinical studies
examine the investigational molecule
under controlled conditions.
Retatrutide is not an authorised UK
medicine. The advertised 40mg quantity
is a product designation, not a
recommended clinical dose.

What Is Retatrutide 40mg?
Retatrutide is a synthetic investigational
peptide developed to activate three
hormone receptors involved in metabolic
regulation: glucose-dependent
insulinotropic polypeptide (GIP),
glucagon-like peptide-1 (GLP-1)
and glucagon.
Its triple-receptor mechanism is being
investigated in obesity, glucose
metabolism and energy-balance research.
These findings concern controlled
investigational formulations rather
than the independently unverified
contents of this commercial product.
How Does Retatrutide Work?
Retatrutide is classified as a
triple hormone receptor agonist.
Its mechanism involves three
metabolic signalling pathways.
GLP-1 Receptor
GLP-1 signalling contributes to
glucose-dependent insulin secretion,
appetite regulation and
gastrointestinal function.
GIP Receptor
GIP signalling plays a role in
glucose-dependent insulin responses
and metabolic regulation.
Glucagon Receptor
Glucagon receptor signalling is
involved in hepatic glucose
metabolism and energy regulation.
The combined receptor activity
distinguishes retatrutide from
single- and dual-receptor agonists.
Its effects continue to be evaluated
in scientific and clinical research.
Retatrutide Research Applications
Obesity and Body-Weight Research
Randomised clinical trials have
investigated retatrutide in adults
with obesity. Published studies
examine body-weight changes and
related metabolic outcomes.
Glucose and Hormonal Signalling
Researchers study how activation
of GIP, GLP-1 and glucagon receptors
affects glucose regulation and
hormone-related metabolic pathways.
Energy Balance
Scientific research also examines
interactions between appetite-related
signalling, energy expenditure and
metabolic responses.
Research distinction:
Clinical findings about investigational
retatrutide do not establish the
composition, safety or effectiveness
of this commercial pen kit.
Retatrutide 40mg Technical Specifications
The following information separates
the product’s advertised designation
from specifications requiring
independent verification.
| Product name | Retatrutide 40mg Injection Pen Kit |
|---|---|
| Compound | Retatrutide (LY3437943) |
| Classification | Investigational triple receptor agonist |
| Receptor targets | GIP, GLP-1 and glucagon |
| Advertised quantity | 40mg; batch content unverified |
| Product presentation | Pen-style packaging shown in the supplied product photograph |
| Physical formulation | Not independently confirmed |
| Kit contents | Not independently confirmed |
| Analytical purity | No verified batch-specific result |
| Certificate of Analysis | Availability not confirmed |
| Storage conditions | Batch-specific instructions required |
| UK clinical status | Not an authorised medicine |
Formulation and Stability Research
Peptide stability can be influenced
by formulation composition, temperature,
moisture, packaging and environmental
exposure.
Analytical methods such as chromatography
and mass spectrometry may support
compound characterisation. Appropriate
stability testing depends on the
formulation being evaluated.
No shelf life, preservative system,
concentration or validated stability
period has been confirmed for this kit.
Storage and Laboratory Handling
Appropriate storage conditions depend
on the verified formulation and
manufacturer documentation.
Laboratory personnel should consult
authentic batch-specific technical
documentation and applicable safety
procedures before handling research
materials.
No specific refrigeration temperature,
reconstitution procedure or beyond-use
period can be established from the
available product information.
Quality Assurance and Batch Documentation
Reliable peptide characterisation
requires documentation specific
to the material and batch.
Relevant records may include
compound identity testing,
chromatographic purity analysis,
batch identifiers, analytical
methods and test dates.
Documentation status:
A verified batch-specific Certificate
of Analysis has not been supplied
for this product listing.
HPLC purity alone does not establish
sterility, endotoxin control,
accurate concentration or
suitability for injection.
Retatrutide 40mg Frequently Asked Questions
What is Retatrutide 40mg?
It is a product designation referring
to a nominal 40mg quantity of
retatrutide, an investigational
triple receptor agonist.
How does retatrutide work?
Retatrutide activates GIP, GLP-1
and glucagon receptors involved
in metabolic regulation.
Is retatrutide approved in the UK?
No. Retatrutide remains investigational
and is not authorised for routine
clinical use in the UK.
Is retatrutide the same as tirzepatide?
No. Retatrutide has activity
at three hormone receptors,
while tirzepatide activates
GIP and GLP-1 receptors.
What is included in the 40mg pen kit?
The precise formulation, accessories
and supplied components require
independent confirmation.
Does 40mg represent a clinical dose?
No. The advertised quantity
does not establish an approved
or recommended clinical dose.
Is a Certificate of Analysis available?
Batch-specific COA availability
has not been confirmed for
this product.
Where can I read retatrutide research?
Peer-reviewed clinical publications
and manufacturer research information
provide evidence about the
investigational molecule.
Related Retatrutide Research Resources
Explore additional educational
information about retatrutide
and metabolic peptide research.
Scientific References
- Jastreboff AM et al.
Triple-Hormone-Receptor Agonist
Retatrutide for Obesity:
A Phase 2 Trial.
New England Journal of Medicine
. - Eli Lilly.
What to Know About Retatrutide.
Scientific research overview
.
Important research information:
Retatrutide remains investigational.
This page provides scientific and
product-catalogue information only.
It does not establish that the
pictured product is clinically
tested, sterile, authorised or
suitable for human or veterinary
administration.







Reviews
There are no reviews yet.